التفاصيل البيبلوغرافية
| العنوان: |
Predictors of galcanezumab response in a real-world study of Korean patients with migraine. |
| المؤلفون: |
Kim, Seung Ae1,2 (AUTHOR), Jang, Hyemin3,4 (AUTHOR), Lee, Mi Ji1,2 (AUTHOR) mirony.lee@gmail.com |
| المصدر: |
Scientific Reports. 9/8/2023, Vol. 13 Issue 1, p1-7. 7p. |
| مصطلحات موضوعية: |
*SUMATRIPTAN, *MEDICATION overuse headache, *KOREANS, *MIGRAINE, *CALCITONIN gene-related peptide, *LOGISTIC regression analysis, *MONOCLONAL antibodies |
| مستخلص: |
To assess factors associated with galcanezumab response in a real-world study of Korean patients with migraine. Predictors of the efficacy of monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP(-R) mAb) have been rarely investigated in Asians. We prospectively recruited and followed up patients with migraine who received monthly galcanezumab treatment in a single university hospital from June 2020 to October 2021. We defined the treatment response with ≥ 50% reduction in moderate/severe headache days in the 3rd month of treatment compared to baseline. Responders and non-responders were compared in terms of demographics, disease characteristics and severity, and previous response to migraine prophylactic treatments. Potential predictors of anti-CGRP(-R) mAb response were tested by using the univariable and multivariable logistic regression analyses. Among 104 patients (81.7% female; mean age 42.0 ± 13.02; 76.9% chronic migraine; and 45.5% medication overuse headache) included, 58 (55.7%) were responders. Non-responders had more chronic migraine, medication overuse headache, monthly headache days, days with acute medication, and daily headaches (i.e. chronic migraine persisting everyday without remission). The multivariable logistic analysis showed chronic migraine (OR 0.05 [95% CI 0.00–0.82], p = 0.036) and the number of previously failed preventive medication classes (OR 0.55 [95% CI 0.33–0.92], p = 0.024] were independently associated with treatment response. Chronic migraine and multiple failures from preventive medication are associated with poor galcanezumab response. Further studies are needed to investigate if earlier treatment before disease chronification or multiple failures may lead to a greater therapeutic gain from anti-CGRP(-R) mAb treatment. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder